 CAMBRIDGE, Mass. MONTREAL--BUSINESS WIRE--Repare Therapeutics Inc. Repare or the Company Nasdaq: RPTX, a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics ANE Conference concerning an upcoming oral presentation of initial monotherapy clinical data from its ongoing Phase 12 clinical trial of R 